Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 25,261 | 25,950 | 19,745 | 18,804 | 13,299 |
| Cost of Goods | 7,893 | 7,881 | 5,886 | 5,426 | 4,217 |
| Gross Profit | 17,368 | 18,069 | 13,859 | 13,378 | 9,082 |
| Operating Expenses | 80,482 | 80,554 | 87,468 | 84,141 | 79,311 |
| Operating Income | -62,221 | -61,604 | -72,723 | -70,337 | -70,012 |
| Interest Expense | 1,931 | 1,573 | 1,571 | 1,569 | 1,560 |
| Other Income | -190 | 79 | -82 | -291 | -67 |
| Pre-tax Income | -64,342 | -63,098 | -74,376 | -72,197 | -71,639 |
| Net Income Continuous | -64,342 | -63,098 | -74,376 | -72,197 | -71,639 |
| Net Income | $-64,342 | $-63,098 | $-74,376 | $-72,197 | $-71,639 |
| EPS Basic Total Ops | -0.94 | -0.92 | -1.10 | -1.07 | -1.08 |
| EPS Basic Continuous Ops | -0.94 | -0.92 | -1.10 | -1.07 | -1.08 |
| EPS Diluted Total Ops | -0.94 | -0.92 | -1.10 | -1.07 | -1.08 |
| EPS Diluted Continuous Ops | -0.94 | -0.92 | -1.10 | -1.07 | -1.08 |
| EBITDA(a) | $-56,424 | $-55,765 | $-67,171 | $-65,032 | $-65,516 |